T2 Biosystems (TTOO) Stock Price, News & Analysis

Company Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $0.14 to $0.15
• 50-Day Range: $0.09 to $0.18
• 52-Week Range: $0.06 to $6.80
• Volume: 104,121 shs
• Average Volume: 585,935 shs
• Market Capitalization: $3.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

T2 Biosystems Stock Analysis - MarketRank™

T2 Biosystems scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

T2 Biosystems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

T2 Biosystems has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of T2 Biosystems has been sold short.

Short Interest Ratio / Days to Cover

T2 Biosystems has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in T2 Biosystems has recently increased by 60.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

T2 Biosystems does not currently pay a dividend.

Dividend Growth

T2 Biosystems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of T2 Biosystems has been sold short.

Short Interest Ratio / Days to Cover

T2 Biosystems has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in T2 Biosystems has recently increased by 60.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.50

News Sentiment

T2 Biosystems has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for T2 Biosystems this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for TTOO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added T2 Biosystems to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, T2 Biosystems insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.03% of the stock of T2 Biosystems is held by insiders.

Percentage Held by Institutions

Only 23.18% of the stock of T2 Biosystems is held by institutions.

TTOO Stock Analysis - Frequently Asked Questions

How have TTOO shares performed this year?

T2 Biosystems' stock was trading at $0.42 at the beginning of 2025. Since then, TTOO stock has decreased by 66.0% and is now trading at $0.1430.
View the best growth stocks for 2025 here.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings results on Monday, July, 29th. The medical equipment provider reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.31. The medical equipment provider had revenue of $1.95 million for the quarter.
Read the conference call transcript.

When did T2 Biosystems' stock split?

T2 Biosystems's stock reverse split before market open on Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that T2 Biosystems investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Digital Turbine (APPS) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/29/2024
• Today: 6/14/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TTOO
• CIK: 1492674
• Web: www.t2biosystems.com
• Phone: (781) 761-4646
• Fax: 781-357-3080
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +3,396.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.08 million
• Net Margins: -563.16%
• Pretax Margin: -559.52%
• Return on Equity: N/A
• Return on Assets: -174.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: $7.68 million
• Price / Sales: 0.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.91) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 21,043,000
• Free Float: 21,037,000
• Market Cap: $3.01 million
• Optionable: Optionable
• Beta: 0.48